CMAC (Continuous Manufacturing and Advanced Crystallisation), a pre-competitive consortium led by the University of Strathclyde to accelerate progress in pharmaceutical manufacturing, announces that Pfizer Inc has joined as a strategic member, alongside GSK, AZ, Novartis, Bayer, Takeda, Lilly and Roche.
CMAC is a world-class national centre in advanced pharmaceutical manufacturing, focusing on accelerating the adoption of continuous manufacturing for the production of medicines with a lower cost and improved sustainability.
Professor Alastair Florence of Strathclyde, Director of the CMAC EPSRC Research Future Manufacturing Research Hub, said: “Pfizer’s interests in continuous manufacturing are aligned with our Hub program, especially our common goal of improving development efficiency and manufacturing through digital design.”
“We are delighted to join CMAC and look forward to working together with other members to advance the pharmaceutical manufacturing process,” said Nick Thomson, Senior Director Technology API at Pfizer.
CMAC Industry Director Craig Johnston said: “It is a pleasure to welcome Pfizer as a new partner company. This further demonstrates CMAC’s global position, and strengthens the impact and value we deliver through our collaborative manufacturing research.”
The CMAC Future Manufacturing Research Hub is one of six hubs established around the UK in 2017 with funding from the UK government through the Engineering and Physical Sciences Research Council (EPSRC). It was developed in response to the need for innovative manufacturing processes to develop today’s medicines and high-value products. They are also developing new flexible, integrated processing technologies to enable the supply chains of the future for new medicines.
In addition to the research team at Strathclyde, the Hub brings together leading academic groups at the Universities of Bath, Cambridge, Leeds, Loughborough, Sheffield and Imperial College London.